8 06, 2018

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By |2018-06-08T08:10:58+00:00June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]

6 06, 2018

Esketamine nasal spray prevails in phase 3 trials

By |2018-06-06T07:29:40+00:00June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

5 06, 2018

MDMA-Assisted Psychotherapy Improves PTSD

By |2018-06-05T15:12:24+00:00June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

5 06, 2018

Letter to the Editor: The Utilization of Atypical Antipsychotics in the Pain Medicine Physician’s Armamentarium

By |2018-06-08T16:47:30+00:00June 5th, 2018|Uncategorized|0 Comments

By Omar Viswanath MD Dear Editor, I read with great interest the recent article by Jimenez et al, A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. The article states “many psychopharmacologic agents are used as primary or adjuncts in pain [...]

1 06, 2018

An Alzheimer’s Antibiotic Receives Initial Funding

By |2018-06-01T09:11:54+00:00June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]

24 05, 2018

Three-year Naturalistic Study On Early Use Of Long-acting Injectable Antipsychotics In First Episode Psychosis

By |2018-06-08T16:47:33+00:00May 24th, 2018|Uncategorized|0 Comments

By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these stud- ies represent a minority of patients [...]

24 05, 2018

An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature

By |2018-06-08T16:48:07+00:00May 24th, 2018|Uncategorized|0 Comments

By Marcela Almeida and Heather Burrell-Ward To the editor, We read with great interest the article by S. Thippaiah and colleagues in a recent issue of the journal. The authors reported the interesting case of a 19-year-old woman who presented with cyclical changes in mood and behavior, alternating between depression and [...]

11 05, 2018

A Review of Clinical Literature: Stimulants, Insomnia and Psychiatric Comorbidity in Veterans

By |2018-05-11T16:26:32+00:00May 11th, 2018|We Know Psychiatry|0 Comments

Prescription Stimulant Use, Misuse, and Motivations Approximately 16 million US adults used prescription stimulants in the preceding year (annual average), 5 million misused prescription stimulants without use disorders, and 0.4 million had use disorders, according to a recent study. Researchers conducted a nationally representative household population study of adults aged [...]

9 05, 2018

News From the APA Convocation: Antipsychotics, Opioids, and PTSD

By |2018-05-09T13:04:15+00:00May 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Study Shows Continued Use of Certain Antipsychotics During Pregnancy May Increase Risk of Gestational Diabetes New York, NY. Women who take certain antipsychotic medications and continue the use of these medications through pregnancy may be at increased risk for gestational diabetes, according to new research published online today by the American Journal of [...]

9 05, 2018

Efficacy of Vortioxetine in Working Patients with GAD

By |2018-06-01T15:19:29+00:00May 9th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Background Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). This post-hoc analysis evaluates the efficacy of vortioxetine in GAD subjects who are working and/or pursuing an education. Methods In study NCT00744627, 301 GAD subjects were randomized to [...]